Hospira, a Pfizer company is voluntarily recalling two lots of naloxone hydrochloride injection, USP – an antidote for opioid overdose – because of the possible presence of particulate matter on the syringe plunger.
The contaminated doses were sent to wholesalers, distributors, and hospitals in the United States, Puerto Rico, and Guam between February 2017 and February 2018. The manufacturer is asking suppliers to discontinue using and distributing the recalled products and notify anyone who may have received them, including stores, pharmacies, and hospitals. The FDA has not received any reports of patient harm due to the possible contamination.
Naloxone can quickly restore normal respiration to someone whose breathing has slowed or stopped due to an opioid overdose. The drug used to be carried only by hospitals, but, in response to the opioid abuse epidemic, many first responders, medical professionals, and family members now keep the drug on hand for emergencies. Naloxone is available without a prescription in some areas of the country.
Bethany Hoffman is a Senior Editor for HealthCentral’s Cancer beat. She strives to reach health consumers on their own terms, empowering them to understand and act upon the health information that affects their lives so they can make effective, engaged choices. To do this, she is a passionate observer of how health, illness, and disability affect the human experience.